Curated Gut Microbiomes for Disease Treatment

BiomeBank is a clinical-stage biotechnology company focused on developing novel microbial therapies aimed at restoring gut microbial ecology to treat and prevent diseases. Central to their approach is the Consortiome™, a breakthrough co-culturing platform that enables the creation of complex synthetic bacterial communities that replicate the diversity of a healthy human gut microbiome. This platform allows BiomeBank to engineer bespoke therapies with targeted functions, significantly reducing production costs compared to traditional donor-derived microbial products. The Consortiome™ contains over 90% of the known gene families found in a healthy microbiome, making it a powerful tool for addressing various chronic diseases linked to gut microbial diversity loss.

The company has a strong track record in commercialization, having developed the world’s first regulator-approved microbiome therapy for treating recurrent Clostridioides difficile infection. BiomeBank's innovative therapies are designed to restore lost microbial functions and target specific diseases, such as ulcerative colitis, through a human-first model of drug discovery that leverages real-world data. Their commitment to advancing microbiome research is further supported by partnerships with leading biomedical organizations, positioning BiomeBank as a potential global leader in the burgeoning field of microbial therapies.

Australia

BiomeBank's mission is to treat and prevent disease by restoring gut microbial ecology

1330 boiling springs rd, adelaide, south australia, australia

BiomeBank

Company Details